Mark T. Reding

Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART)

Marilyn J. Manco‐Johnson, Christine L. Kempton, Mark T. Reding et al. · Journal of Thrombosis and Haemostasis · 2013 · 198 citations · Full text

Medicine, Hematology, Pharmacotherapy +13

Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A

Johnny Mahlangu, Radosław Kaczmarek, Annette von Drygalski et al. · New England Journal of Medicine · 2023 · 191 citations · Full text

Medicine, Hematology, Pharmacotherapy +14

Phase I study of BAY 94‐9027, a PEGylated B‐domain‐deleted recombinant factor VIII with an extended half‐life, in subjects with hemophilia A

Thomas Coyle, Mark T. Reding, Jennifer Lin et al. · Journal of Thrombosis and Haemostasis · 2014 · 143 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

Effect of late prophylaxis in hemophilia on joint status: a randomized trial

Marilyn J. Manco‐Johnson, Björn Lundin, Sharon Funk et al. · Journal of Thrombosis and Haemostasis · 2017 · 127 citations · Full text

Medicine, Hematology, Orthopedic Surgery +13

Distribution of Th1- and Th2-induced Anti-factor VIII IgG Subclasses in Congenital and Acquired Hemophilia Patients

Sijin Lei, Howard Lei, D. Green et al. · Thrombosis and Haemostasis · 2002 · 121 citations

Life Sciences, Hematology, Immunology +15